Health Care/Hospital
NUS scientists harness magnetic pulses to reprogram immune cells to fight breast cancer
An innovative approach for breast cancer treatment uses localised and non-invasive pulsed electromagnetic fields to reprogram immune cells, turning them from tumour helpers to cancer killers SINGAPORE, Sept. 14, 2026 /PRNewswire/ -- Researchers from the National University of Singapore (NUS) hav...
2026-09-14 14:14
1
Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland
- Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia's Longevity Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference - TOKYO and GSTAAD, Switzerland, Sept. 14, 2026 /PRNewswire/ -- Abe Yoando Pharma Co., Ltd., a nearly 300-year-old pharmaceutical ...
2026-09-14 14:00
181
Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development
NEW YORK and SUZHOU, China, Sept. 13, 2026 /PRNewswire/ -- On September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring Plan-Extension", known in Chin...
2026-09-14 10:00
969
Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organ...
2026-09-13 14:59
2994
POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today a...
2026-09-10 20:00
2054
TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection
— Phase IIb multicenter trial initiated, bringing this potential life-changing therapy closer to patients — SUZHOU, China, Sept. 10, 2026 /PRNewswire/ -- TenNor Therapeutics, a near-commercial-stage biotechnology company, today announced positive topline results from a Phase IIa proof-of-concept...
2026-09-10 19:30
2085
Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial
LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigati...
2026-09-09 20:25
2033
Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies
PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its su...
2026-09-09 20:00
1696
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy
* Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer * Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth q...
2026-09-09 19:12
1895
Health In Tech Named to Newsweek's America's Greatest Mid-Market Companies 2026
Health In Tech recognized among the 100 highest-scoring U.S. public mid-market companies following an initial review of approximately 4,300 companies, based on financial strength, workforce performance, innovation and sustainability STUART, Fla., Sept. 9, 2026 /PRNewswire/ -- Health In Tech, Inc....
2026-09-09 18:30
1336
HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit
HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. TAIPEI and SHANGHAI and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developi...
2026-09-09 18:00
1408
Natural Field Expands NF TriSolve® Platform Into Sleep Wellness With Science-Driven Nutraceutical Innovation
SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Natural Field, a technology-driven nutraceutical ingredient solutions provider, announced the expansion of its NF TriSolve® branded nutraceutical solution platform into the growing sleep wellness category with the introduction of NF TriSolve® SleepRestore ...
2026-09-08 22:00
2383
Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026
Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and preci...
2026-09-08 21:00
2367
GROWNSY Partners with Graham's Foundation During NICU Awareness Month to Support NICU Families Beyond the Hospital Stay
NEW YORK, Sept. 8, 2026 /PRNewswire/ -- GROWNSY, a baby care brand trusted by more than 3 million households worldwide, today announced a new long-term partnership with Graham's Foundation, a nonprofit organization dedicated to supporting parents of premature babies. The partnership will begin d...
2026-09-08 21:00
1557
Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ...
2026-09-08 20:20
1453
HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. * HBM9378/WIN378 produc...
2026-09-08 20:17
1682
Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend
BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited financial results for the three and six months ended J...
2026-09-08 18:00
4491
/C O R R E C T I O N -- GCCL/
In the news release, "GCCL Strengthens Asia-Pacific Presence at Asia Bio Partnering Forum 2026," issued on September 8, 2026 by GCCL over PR Newswire, we are advised by the company that the name "Yoo-Hwa Choi" should read "Yuhwa Choi" throughout the release, as originally issued inadvertently. Co...
2026-09-08 16:05
1953
Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. SHANGHAI, Sept. 7, 2026 /PRNewswire/ -- On September 7, 2026, Shanghai, Cell Stem Cell published online clini...
2026-09-08 08:00
1513
U.S. District Court Invalidates Kaneka's Ubiquinol Patent, Clearing the Way for Cocrystal Tech's CrysQnol™ in the U.S. Market
Judge Overturns Kaneka's '080 Patent for Lack of Utility and Enablement, Removing Legal Uncertainty for Customers and Partners JIAXING, China, Sept. 7, 2026 /PRNewswire/ -- Cocrystal Technology (Jiaxing) Co., Ltd. ("Cocrystal Tech")today announced that the U.S. District Court for the Eastern Dis...
2026-09-07 20:30
3808
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Nuix Expands Generative AI for Legal Review, Debuts AI Chat for Case Data
[Picked up by 262 media titles]
2026-09-07 09:40Most Read
AIA Australia, Long Service Corporation, New Zealand Police and RMBL Investments Named 2026 Appian APJ Innovation Award Winners
2026-09-07 11:28
9711
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
9110
